Suárez-Cuenca Juan Antonio, Campos-Nolasco Nuri Perla, Rodríguez-Ayala Ernesto, Zepeda-Làmbarry Ana Daniela, Ochoa-Madrigal Marta Georgina, Maldonado-Tapia Diana, Vera-Gómez Eduardo, Hernández-Patricio Alejandro, Martínez-Torres Gustavo, Bernal-Figueroa Yareni, Pineda-Juárez Juan Antonio, Gutiérrez-Salinas José, Toledo-Lozano Christian Gabriel, García Silvia
Laboratorio de Metabolismo Experimental e Investigación Clínica, División de Investigación, Centro Médico Nacional "20 de Noviembre", Mexico City, Mexico.
Unidad de Hemodialisis, Clínica de Especialidades "Dr. Alberto Pisanty Ovadia", Mexico City, Mexico.
Ren Fail. 2025 Dec;47(1):2463561. doi: 10.1080/0886022X.2025.2463561. Epub 2025 Feb 17.
Neurotrophins are related with depressive disorders. Significant neurotrophins variations occur during renal replacement therapy, but whether peri-hemodialysis availability is associated with depression in patients with Chronic Kidney Disease (CKD) is yet unclear.
To determine dynamic concentrations of neurotrophins in the peri-hemodialysis range and their association with depressive symptoms in patients with CKD.
Pre-, and post-hemodialysis plasma concentrations of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), as well as their plasma clearance rates, were determined (multiplexing) in patients with stage 5 CKD. Depressive symptoms, as assessed by the Beck Depression Inventory-II (BDI-II), were determined. Finally, the bioavailability of BDNF and NGF was related to the score of depressive symptoms.
Fifty-three patients were divided according to depressive symptoms. Pre-hemodialysis plasma BDNF was lower in patients with depressive disorder; whereas basal BDNF value >220 pg/mL independently reduced the risk for depressive disorder (Odds Ratio 0.23, = 0.047) at uni- and multivariate analysis. Post-hemodialysis concentration and clearance rate of neurotrophins were not related with depressive symptoms.
Higher plasma BDNF before hemodialysis reduces the risk of mild depression in patients with CKD under renal replacement therapy.
神经营养因子与抑郁症有关。在肾脏替代治疗期间神经营养因子会发生显著变化，但慢性肾脏病（CKD）患者血液透析前后神经营养因子的可用性是否与抑郁症相关尚不清楚。
确定CKD患者血液透析前后神经营养因子的动态浓度及其与抑郁症状的关系。
对5期CKD患者进行血液透析前、后血浆脑源性神经营养因子（BDNF）和神经生长因子（NGF）浓度以及血浆清除率的多重检测。采用贝克抑郁量表第二版（BDI-II）评估抑郁症状。最后，将BDNF和NGF的生物利用度与抑郁症状评分相关联。
53例患者根据抑郁症状进行分组。抑郁症患者血液透析前血浆BDNF较低；单因素和多因素分析显示，基础BDNF值>220 pg/mL可独立降低患抑郁症的风险（比值比0.23，P = 0.047）。血液透析后神经营养因子的浓度和清除率与抑郁症状无关。
血液透析前较高的血浆BDNF水平可降低接受肾脏替代治疗的CKD患者发生轻度抑郁的风险。
